---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-017206"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:05:56.147158+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q1 revenue $22.6M (+31% YoY), net loss narrows to $1.9M, raises 2023 outlook

## Summary
- Record Q1 net sales $22.6M (+31% YoY); Tru Niagen contributed $17.6M.
- Gross margin 59.9%; SG&A as % of sales improved to 34.9% from 47.7%.
- Net loss $1.9M ($0.03 EPS) vs $7.7M ($0.11 EPS) in Q1 2022; Adjusted EBITDA loss only $0.1M.
- Raised conservative end of 2023 revenue outlook to 12.5% growth; generated $2.8M positive operating cash flow.
- Operating expenses reduced $2.8M (-15%) driven by lower legal, share-based comp, and severance costs.

## SEC filing metadata
- accession: 0001628280-23-017206
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/0001628280-23-017206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/cdxc-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-017206
- JSON: https://secwatch.observer/filing/0001628280-23-017206.json
- Plain text: https://secwatch.observer/filing/0001628280-23-017206.txt

## Key facts
- Earnings Releases
  Niagen Bioscience, Inc. reported the three months ended March 31, 2023 results: revenue $22.6 million, net income $1.9 million, EPS $(0.03) per share.
  - Period: the three months ended March 31, 2023
  - Revenue: $22.6 million
  - Net income: $1.9 million
  - EPS: $(0.03) per share
  - Result: reported results
  source text: ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/0001628280-23-017206-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.